Last quarter (Q4 2022), Paradigm Biopharmaceuticals Ltd.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Paradigm Biopharmaceuticals Ltd.'s net income was $―. See Paradigm Biopharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	$ ―	$ 79.22K	$ 20.55K	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ 143.75K	$ 99.14K	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ -64.53K	$ -78.59K	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 47.93M	$ 43.31M	$ 17.04M	$ 10.22M	$ 8.93M
Operating Income	$ ―	$ -47.99M	$ -43.39M	$ -17.04M	$ -10.22M	$ -8.93M
Net Non Operating Interest Income Expense	$ ―	$ 23.11K	$ 171.40K	$ 963.48K	$ 261.71K	$ 53.90K
Other Income Expense	$ ―	$ 8.66M	$ 8.71M	$ 3.70M	$ -5.67M	$ 2.68M
Pretax Income	$ ―	$ -39.25M	$ -34.30M	$ -12.30M	$ -15.63M	$ -6.19M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -39.25M	$ -34.30M	$ -12.30M	$ -15.63M	$ -6.19M
Basic EPS	$ ―	$ -0.17	$ -0.17	$ -0.06	$ -0.11	$ -0.05
Diluted EPS	$ ―	$ -0.17	$ -0.17	$ -0.06	$ -0.11	$ -0.05
Basic Average Shares	$ ―	$ 234.37M	$ 204.90M	$ 201.11M	$ 143.04M	$ 116.17M
Diluted Average Shares	$ ―	$ 234.37M	$ 204.90M	$ 201.11M	$ 143.04M	$ 116.17M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -39.25M	$ -34.30M	$ -12.30M	$ -15.63M	$ -6.19M
Normalized Income	$ ―	$ -39.25M	$ -34.30M	$ -12.30M	$ -8.70M	$ -6.19M
Interest Expense	$ ―	$ 28.63K	$ 37.72K	$ 34.17K	$ ―	$ ―
EBIT	$ ―	$ -39.22M	$ -34.26M	$ -12.26M	$ -10.22M	$ -8.93M
EBITDA	$ ―	$ -39.16M	$ -34.05M	$ -12.19M	$ -10.22M	$ -8.93M

Currency in USD

Paradigm Biopharmaceuticals Ltd. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing